Page 113 - Aet News Today

Pear Therapeutics was once regarded as a digital therapeutics pioneer, but its spiral into bankruptcy has the industry searching for the best path forward. While some favor going direct to consumers, others say the solution is in generating more robust clinical trial data to persuade hesitant payers.

The webinar, sponsored by Intelligent Medical Objects, will explore the impact of poor data quality and methods to improve patient data quality. It will also highlight healthcare industry employee burnout and how to improve retention.

Octave Bioscience, based in Menlo Park, California, just closed a $30 million extension to its Series B funding round.

Social media should play a bigger part in public health crisis planning, according to a recent analysis. The analysis explored the crucial role that Twitter and other social media platforms played when the app for Abbott’s FreeStyle Libre system crashed earlier this month in the U.K.

In 2020, 46.9% of all novel drugs approved by the FDA were for rare diseases, as compared to 23.5% in 2012. Investment is expected to continue trending upward, with estimates suggesting that global spending on rare disease therapies will reach $260 billion by the end of 2025.

At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.

Astellas Pharma has identified targeted protein degradation as one of the key areas for growth. The PeptiDream alliance is the latest one Astellas has struck in this particular area of drug research as it aims to find new ways to go after difficult cancer targets.

About 36% of U.S. hospitals are in compliance with CMS' price transparency rule, up from 24.5% in February, according to a new report. This progress will remain slow unless CMS can do a better job of effectively enforcing its rule, the report declared.

Patients are driving the push away from needles, and there are a number of novel approaches attempting to solve the difficult task of transforming biologics into orally administered treatments.

Alnylam pioneered RNA interference drugs for rare disease. The biotech aims to bring RNAI to prevalent disorders and its alliance with Roche on the drug zilebesiran for hypertension better positions the company to achieve this goal.